Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Katayama Y, et al. Among authors: takayama k. JTO Clin Res Rep. 2023 Mar 7;4(4):100494. doi: 10.1016/j.jtocrr.2023.100494. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37020925 Free PMC article.
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.
Hibino M, Hiranuma O, Takemura Y, Katayama Y, Chihara Y, Harada T, Fujita K, Kita T, Tamiya N, Tsuda T, Shiotsu S, Tamura Y, Aoyama T, Nakamura Y, Terashima M, Morimoto Y, Nagata K, Yoshimura K, Uchino J, Takayama K. Hibino M, et al. Among authors: takayama k. JTO Clin Res Rep. 2022 Oct 15;3(12):100424. doi: 10.1016/j.jtocrr.2022.100424. eCollection 2022 Dec. JTO Clin Res Rep. 2022. PMID: 36438852 Free PMC article.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Morimoto K, Yamada T, Sawada R, Azuma K, Goto Y, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Tanaka S, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Morimoto K, et al. Among authors: takayama k. Cancer Immunol Immunother. 2023 Jun;72(6):1699-1707. doi: 10.1007/s00262-023-03370-1. Epub 2023 Jan 9. Cancer Immunol Immunother. 2023. PMID: 36617602 Free PMC article.
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
Ishida M, Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Iwasaku M, Tokuda S, Kim YH, Takayama K. Ishida M, et al. Among authors: takayama k. JTO Clin Res Rep. 2023 Feb 28;4(4):100493. doi: 10.1016/j.jtocrr.2023.100493. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37025120 Free PMC article.
Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
Sakakida T, Ishikawa T, Doi T, Morita R, Kataoka S, Miyake H, Yamaguchi K, Moriguchi M, Sogame Y, Yasuda H, Iwasaku M, Konishi H, Takayama K, Itoh Y. Sakakida T, et al. Among authors: takayama k. J Gastroenterol. 2023 Jun;58(6):575-585. doi: 10.1007/s00535-023-01986-9. Epub 2023 Apr 7. J Gastroenterol. 2023. PMID: 37029223 Free PMC article.
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
Tanimura K, Uchino J, Kimura H, Hiranuma O, Chihara Y, Tanzawa S, Takumi C, Kita T, Inoue K, Minato K, Takemoto S, Nakao A, Yoshimura K, Takayama K. Tanimura K, et al. Among authors: takayama k. Oncologist. 2023 Jun 2;28(6):551-e454. doi: 10.1093/oncolo/oyad013. Oncologist. 2023. PMID: 37053467 Free PMC article. Clinical Trial.
Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer.
Morita-Tanaka S, Miyagawa-Hayashino A, Yamada T, Matsui Y, Morimoto K, Hiranuma O, Masuzawa N, Yoshimura A, Iwasaku M, Tokuda S, Kaneko Y, Kim YH, Konishi E, Takayama K. Morita-Tanaka S, et al. Among authors: takayama k. Support Care Cancer. 2023 Apr 28;31(5):308. doi: 10.1007/s00520-023-07771-x. Support Care Cancer. 2023. PMID: 37115357
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Ishida M, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Morimoto K, et al. Among authors: takayama k. Drugs Aging. 2023 Jun;40(6):563-571. doi: 10.1007/s40266-023-01034-4. Epub 2023 May 5. Drugs Aging. 2023. PMID: 37145245
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).
Kawachi H, Yamada T, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Shimose T, Takayama K. Kawachi H, et al. Among authors: takayama k. Ther Adv Med Oncol. 2023 Jun 12;15:17588359231177022. doi: 10.1177/17588359231177022. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37333903 Free PMC article.
2,165 results